Five-year outcome of respiratory muscle weakness at intensive care unit discharge: secondary analysis of a prospective cohort study.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
06 2021
Historique:
received: 08 12 2020
revised: 02 02 2021
accepted: 18 02 2021
pubmed: 14 3 2021
medline: 14 7 2021
entrez: 13 3 2021
Statut: ppublish

Résumé

To assess the association between respiratory muscle weakness (RMW) at intensive care unit (ICU) discharge and 5-year mortality and morbidity, independent from confounders including peripheral muscle strength. Secondary analysis of the prospective 5-year follow-up of the EPaNIC cohort (ClinicalTrials.gov: NCT00512122), limited to 366 patients screened for respiratory and peripheral muscle strength in the ICU with maximal inspiratory pressure (MIP) after removal of the artificial airway, and the Medical Research Council sum score. RMW was defined as an absolute value of MIP <30 cmH RMW was present in 136/366 (37.2%) patients at ICU discharge. RMW was not independently associated with 5-year mortality (HR with 95% CI 1.273 (0.751 to 1.943), p=0.352). Among 156five-year survivors, those with, as compared with those without RMW demonstrated worse physical function (MIP (absolute value, cmH RMW at ICU discharge is independently associated with 5-year morbidity but not 5-year mortality.

Identifiants

pubmed: 33712505
pii: thoraxjnl-2020-216720
doi: 10.1136/thoraxjnl-2020-216720
doi:

Banques de données

ClinicalTrials.gov
['NCT00512122']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-567

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Nathalie Van Aerde (N)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.

Philippe Meersseman (P)

Medical Intensive Care Unit, Department of General Internal Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Yves Debaveye (Y)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.
Intensive Care Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Alexander Wilmer (A)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.
Medical Intensive Care Unit, Department of General Internal Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Jan Gunst (J)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.
Intensive Care Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Michael P Casaer (MP)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.
Intensive Care Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Joost Wauters (J)

Medical Intensive Care Unit, Department of General Internal Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.
Laboratory for Clinical Infectious and Inflammatory Disorders, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Flanders, Belgium.

Pieter J Wouters (PJ)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.
Intensive Care Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Rik Gosselink (R)

Rehabilitation Sciences, KU Leuven, Leuven, Flanders, Belgium.

Greet Van den Berghe (G)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium.
Intensive Care Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Greet Hermans (G)

Cellular and Molecular Medicine, KU Leuven, Leuven, Flanders, Belgium Greet.Hermans@uzleuven.be.
Medical Intensive Care Unit, Department of General Internal Medicine, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH